Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. blms 4 tb

BLMs 4 TB SIGNED

Beta-lactams for Tuberculosis Treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BLMs 4 TB project word cloud

Explore the words cloud of the BLMs 4 TB project. It provides you a very rough idea of what is the project "BLMs 4 TB" about.

unpleasant    never    tb    modeling    outcomes    tuberculosis    family    severe    subset    frequency    infected    drug    infections    inform    lactams    ram    renewed    poor    bacterial    lapse    linked    deadly    transcriptomic    beneficiary    market    proteomic    track    ineffective    point    validated    24    molecular    glaxosmithkline    treatments    leads    answer    relapse    strains    carbapenem    patients    takes    oacute    undergo    life    agents    dr    cephalosporins    beta    50    pursued    gsk    antibiotics    generation    barros    quality    hope    extensively    months    pharmacokinetic    time    iacute    anti    iia    mdr    longer    head    xdr    first    questions    discontinued    garc    resistant    optimal    administration    treat    last    resistance    trial    combo    dim    decades    killing    regarded    adherence    prevent    unclear    report    outcome    shorten    microbiology    treatment    pharmacodynamics    mathematical    meropenem    pk    therapy    arose    cephems    specificities    techniques    worldwide    positive    blms    data    therapies    trials    microscopy    safest    pd    prospects    carbapenems    infectious    record    led    urgently    clinical    blm    disease    virtually    dosage   

Project "BLMs 4 TB" data sheet

The following table provides information about the project.

Coordinator		 FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO 

Organization address
address: PASEO MARIA AGUSTIN 36 EDIFICIO PIGNATELLI PTA 30 PL 2
city: ZARAGOZA
postcode: 50004
website: www.araid.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO ES (ZARAGOZA) coordinator 170˙121.00

Map

 Project objective

Tuberculosis (TB) is the most deadly infectious disease worldwide. TB therapy takes 6 months with unpleasant side effects that leads to poor adherence and the development of drug resistance. Patients infected with multi (MDR) or extensively (XDR) drug resistant strains must undergo longer treatments (up to 24 months) associated with even severe side effects and only 30-50% positive treatment outcomes. New treatments are urgently needed.

Beta-lactams (BLMs) are the safest antibiotics in the market with a long track record of clinical use to treat bacterial infections. They were, however, traditionally regarded as ineffective for TB therapy to the point that research was virtually discontinued for the last three decades. A renewed interest recently arose after a report of Phase IIa clinical trial validated the potential of meropenem (a carbapenem). This study was led by Dr. Barros, Head TB unit GlaxoSmithKline (GSK) (the beneficiary of this proposal). In addition, Dr. Ramón-García (the applicant) just identified first-generation cephalosporins (cephems), a subset of the BLM family never pursued for TB therapy, as potential anti-TB agents. Promoting BLM development is the best immediate hope for TB patients that currently have very dim life prospects.

Carbapenems and cephems have different anti-bacterial killing properties, pharmacokinetic (PK) and pharmacodynamics (PD) parameters. These specificities affect therapy design for an optimal clinical outcome. Although promising, it is still unclear how BLMs should be included in new combo therapies (i.e. dosage, duration and frequency of administration) to shorten the duration of TB therapy, prevent relapse and treat M(X)DR-TB.

To answer these questions, I will use time-lapse microscopy linked to mathematical PK/PD modeling, transcriptomic and proteomic studies and clinical microbiology techniques to provide high quality molecular and PK/PD pre-clinical data to inform the design of future BLM TB clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BLMS 4 TB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BLMS 4 TB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

POLINGO (2018)

The Politics of Legitimacy: Non-partisan global governance and networked INGO power in the global governance of post-war states

Read More  

CYBERSECURITY (2018)

Cyber Security Behaviours

Read More  

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More